首页> 外国专利> u03c5u03c0u03bfu03bau03b1u03c4u03b5u03c3u03c4u03b7u03bcu03b5u03bdu03b5u03c22,6-u4e8cu6c28u57fa-4-u03bcu03bfu03bdu03bfu03abu03c0u03bfu03bau03b1u03c4u03b5u03c3u03c4u03b7u03bcu03b5u03bdu03b5u03c2u03c0u03c5u03c1u03b9u03bcu03b9u03b4u03b9u03bdu03b5u03c2u4f5cu4e3au7adeu4e89u5bf9u624bu7684u03c0u03c1u03bfu03c3u03c4u03b1u03b3u03bbu03b1u03bdu03b4u03b9u03bdu03c9u03bdu03c5u03c0u03bfu03b4u03bfu03c7u03b5u03c9u03bdD2

u03c5u03c0u03bfu03bau03b1u03c4u03b5u03c3u03c4u03b7u03bcu03b5u03bdu03b5u03c22,6-u4e8cu6c28u57fa-4-u03bcu03bfu03bdu03bfu03abu03c0u03bfu03bau03b1u03c4u03b5u03c3u03c4u03b7u03bcu03b5u03bdu03b5u03c2u03c0u03c5u03c1u03b9u03bcu03b9u03b4u03b9u03bdu03b5u03c2u4f5cu4e3au7adeu4e89u5bf9u624bu7684u03c0u03c1u03bfu03c3u03c4u03b1u03b3u03bbu03b1u03bdu03b4u03b9u03bdu03c9u03bdu03c5u03c0u03bfu03b4u03bfu03c7u03b5u03c9u03bdD2

机译:u u03ab u03c0 u03bf u03ba u03b1 u03c4 u03b5 u03c3 u03c4 u03b7 u03bc u03b5 u03bd u03b5 u03c2 u03c0 u03c5 u03c1 u03b9 b u03c2 u4f5c u4e3a u7ade u4e89 u5bf9 u624b u7684 u03c0 u03c1 u03bf u03c3 u03c4 u03b1 u03b3 u03bb3 u03b03 u03b3 u03bb1 u03bf u03b4 u03bf u03c7 u03b5 u03c9 u03bdD2

摘要

The present invention relates to a chemical formula (I) of a compound, as defined herein, a pharmaceutical composition with a alpha Mu alpha kappa e_ _ _ _ _ _ _uuuuuuu A chemical formula (I) for one or more forms of compounds and an acceptable carrier for a [phi] alpha [phi] alpha [alpha] kappa [e] __], and the efficacy of one method The patients' diseases include Rho gD2 dependence.But without limitations, allergic diseases (such as allergic rhinitis, allergic conjunctivitis, allergic dermatitis, bronchial asthma, and food) The disturbance system is accompanied by a system of_________activation cells, allergic kappa___activation cells, and allergic kappa____95 In October 2004, the expressions of beta, gamma, gamma, urticaria, eczema, etc.Diseases with itching (such as atopic dermatitis, urticaria), diseases (such as cataracts, retina alpha_uuuuuuuuuuuuuuuuuuuuuuu Thus, the emergence of inflammation, infection, and secondary sleep disorders as a result of a behavior (such as scratching with itching) (1) inflammation, chronic lung disease, alpha P1, P, P, and so on.Ischemia-reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, ulcerative colitis and the segment of __delta alpha_;;;;;;;;; Similarly, a chemical formula (I) was given to these patients for a coalition of active doses of [alpha] P [alpha] [alpha] [alpha] kappa [alpha] [alpha] [alpha] [alpha] kappa [alpha] [alpha] [alpha] [alpha] [alpha] [alpha] [alpha] [alpha
机译:技术领域本发明涉及如本文所定义的化合物的化学式(I),具有αMuα-κ的药物组合物。一种或多种形式的化合物的化学式(I)和φαφαακ的可接受载体,以及一种方法的功效患者的疾病包括Rho gD2依赖性。但不限于,变应性疾病(例如变应性鼻炎,变应性结膜炎,过敏性皮炎,支气管哮喘和食物)干扰系统伴有_________活化细胞,过敏性κ_活化细胞和过敏性κ_95的系统.2004年10月,β,γ,γ,荨麻疹,湿疹等的表达与瘙痒(如特应性皮炎,荨麻疹),疾病(如白内障,视网膜) g带有瘙痒)(1)炎症,慢性肺部疾病,αP1,P,P等。缺血再灌注损伤,脑血管意外,慢性类风湿性关节炎,溃疡性结肠炎和δδ段;;;;; ;;;类似地,向这些患者给出化学式(I),以联合有效剂量的αPαααακααααακα αααααααα

著录项

获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号